Literature DB >> 12351623

Stimulus-specific requirements for MAP3 kinases in activating the JNK pathway.

Wei Chen1, Michael A White, Melanie H Cobb.   

Abstract

Mitogen-activated protein kinases (MAPKs) are activated by numerous ligands typically through a protein kinase cascade minimally composed of the MAPK in series with a MAP2 kinase (MAP2K) and a MAP3K. This arrangement is thought to confer specificity and appropriate kinetic properties on the activation of MAPKs in response to physiological stimuli. Surprisingly, more than a dozen MAP3Ks have been identified that activate the c-Jun N-terminal kinases (JNKs) when overexpressed, but there is no clear understanding of which kinases actually mediate JNK activation by ligands. Here, we use double-stranded RNA-mediated interference of gene expression to reveal the explicit participation of discrete MAP3Ks in controlling JNK activity by multiple stimuli. Maximal activation of JNK by lipopolysaccharide requires the MAP3K TAK1. On the other hand, sorbitol requires expression of four MAP3Ks to cause maximal JNK activation. Thus, we demonstrate that specific stimuli use different mechanisms to recruit distinct MAP3Ks to regulate the JNK pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351623     DOI: 10.1074/jbc.M204934200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Ubiquitin signalling in the NF-kappaB pathway.

Authors:  Zhijian J Chen
Journal:  Nat Cell Biol       Date:  2005-08       Impact factor: 28.824

2.  Generation of a conditional mutant allele for Tab1 in mouse.

Authors:  Maiko Inagaki; Yoshihiro Komatsu; Greg Scott; Gen Yamada; Manas Ray; Jun Ninomiya-Tsuji; Yuji Mishina
Journal:  Genesis       Date:  2008-08       Impact factor: 2.487

3.  TAK1-binding protein 1, TAB1, mediates osmotic stress-induced TAK1 activation but is dispensable for TAK1-mediated cytokine signaling.

Authors:  Maiko Inagaki; Emily Omori; Jae-Young Kim; Yoshihiro Komatsu; Greg Scott; Manas K Ray; Gen Yamada; Kunihiro Matsumoto; Yuji Mishina; Jun Ninomiya-Tsuji
Journal:  J Biol Chem       Date:  2008-10-01       Impact factor: 5.157

4.  The protein Dredd is an essential component of the c-Jun N-terminal kinase pathway in the Drosophila immune response.

Authors:  Silvia Guntermann; Edan Foley
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

5.  Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated NF-kappaB activation: TAO2 regulates TAK1 pathways.

Authors:  Wei-Chun Huangfu; Emily Omori; Shizuo Akira; Kunihiro Matsumoto; Jun Ninomiya-Tsuji
Journal:  J Biol Chem       Date:  2006-08-07       Impact factor: 5.157

6.  Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha.

Authors:  Peter C F Cheung; David G Campbell; Angel R Nebreda; Philip Cohen
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

7.  POSH misexpression induces caspase-dependent cell death in Drosophila.

Authors:  Ashley L Lennox; Beth Stronach
Journal:  Dev Dyn       Date:  2010-02       Impact factor: 3.780

8.  Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.

Authors:  Bart Burington; Bart Barlogie; Fenghuang Zhan; John Crowley; John D Shaughnessy
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

9.  Elucidation of the c-Jun N-terminal kinase pathway mediated by Estein-Barr virus-encoded latent membrane protein 1.

Authors:  Jun Wan; Luguo Sun; Jennifer Woo Mendoza; Yiu Loon Chui; Dolly P Huang; Zhijian J Chen; Nobutaka Suzuki; Shinobu Suzuki; Wen-Chen Yeh; Shizuo Akira; Kunihiro Matsumoto; Zheng-Gang Liu; Zhenguo Wu
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

10.  A non-redundant role for Drosophila Mkk4 and hemipterous/Mkk7 in TAK1-mediated activation of JNK.

Authors:  Peter Geuking; Rajesh Narasimamurthy; Bruno Lemaitre; Konrad Basler; François Leulier
Journal:  PLoS One       Date:  2009-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.